2 research outputs found
Serum biomarkers for pulmonary hypertension
ΠΠ°Π»ΠΈΡΠ΅ ΡΠ° Π·Π½Π°ΡΠΈΠΌΠΈ ΠΈΠ·ΡΠ»Π΅Π΄Π²Π°Π½ΠΈΡ ΠΈ Π½Π°ΡΡΠ½ΠΈ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ, ΡΠ²ΡΡΠ·Π°Π½ΠΈ Ρ ΠΏΠ°ΡΠΎΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΡΠ° Π½Π° ΠΏΡΠ»ΠΌΠΎΠ½Π°Π»Π½Π°ΡΠ° Ρ
ΠΈΠΏΠ΅ΡΡΠΎΠ½ΠΈΡ (ΠΠ₯), Π²ΡΠ»Π΅Π΄ΡΡΠ²ΠΈΠ΅ Π½Π° ΠΊΠΎΠ΅ΡΠΎ ΡΠ΅ ΡΠ²Π΅Π»ΠΈΡΠ°Π²Π°Ρ Π²ΡΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈΡΠ΅ Π·Π° ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ½ΠΎΡΠΎ ΠΈ ΠΏΠΎΠ²Π»ΠΈΡΠ²Π°Π½Π΅. Π’ΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΠΈΡΠ΅ ΠΌΠ΅ΡΠΎΠ΄ΠΈ Π·Π° Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΠΈ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΡΠ°Π½Π΅ Π½Π° ΠΠ₯ Π²ΠΊΠ»ΡΡΠ²Π°Ρ Π΅Ρ
ΠΎΠΊΠ°ΡΠ΄ΠΈΠΎΠ³ΡΠ°ΡΠΈΡ ΠΈ Π΄ΡΡΠ½Π° ΡΡΡΠ΄Π΅ΡΠ½Π° ΠΊΠ°ΡΠ΅ΡΠ΅ΡΠΈΠ·Π°ΡΠΈΡ, Π΄ΠΎΠΏΡΠ»Π½Π΅Π½ΠΈ ΠΎΡ ΠΎΡΠ΅Π½ΠΊΠ° Π½Π° ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»Π½ΠΈΡ ΠΊΠ»Π°Ρ ΠΏΠΎ NYHA ΠΈ 6-ΠΌΠΈΠ½ΡΡΠ΅Π½ ΡΠ΅ΡΡ Ρ Ρ
ΠΎΠ΄Π΅Π½Π΅ (6 MWT). ΠΠ°ΡΠ°ΡΡΠ²Π°ΡΠΈΡΡ Π±ΡΠΎΠΉ ΡΠΈΡΠΊΡΠ»Π°ΡΠΎΡΠ½ΠΈ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΈ, ΠΊΠΎΠΈΡΠΎ ΡΠ΅ ΠΏΠΎΠ²ΠΈΡΠ°Π²Π°Ρ ΠΏΡΠΈ ΠΠ₯ ΠΌΠΎΠΆΠ΅ Π΄Π° ΠΏΠΎΠ΄ΠΏΠΎΠΌΠΎΠ³Π½Π΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠΈΡΡΠΈΡΠ΅ ΠΊΠ°ΠΊΡΠΎ Π² Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ°ΡΠ°, ΡΠ°ΠΊΠ° ΠΈ ΠΏΡΠΈ ΠΎΡΠ΅Π½ΠΊΠ° ΡΠ΅ΠΆΠ΅ΡΡΡΠ° Π½Π° Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½Π΅ΡΠΎ ΠΈ ΠΎΡΠ³ΠΎΠ²ΠΎΡΠ° ΠΎΡ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ΡΠΎ. In the fi eld of development of pathophysiology of pulmonary hypertension, there are growing number of signifi cant recent advances, which leads to new therapeutic agents. Traditional methods of diagnosing and monitoring this condition have comprised echocardiography and right heart catheterization, in addition to functional measures, such as estimation of functional class and the 6-min walk test. An increasing number of biomarkers have been described that are elevated in pulmonary hypertension and which may assist the clinician in diagnosis and in the assessment of disease severity and response to treatment.